Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05007873 · ClinicalTrials.gov registry record · Phase 2
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
A Phase 2 study of Philadelphia Chromosome Positive and Chronic Phase Chronic Myelogenous Leukemia, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT05007873: Recruiting Phase 2 study of Philadelphia Chromosome Positive and Chronic Phase Chronic Myelogenous Leukemia, sponsored by M.D. Anderson Cancer Center.
NCT05007873 is a Phase 2 study of Philadelphia Chromosome Positive and Chronic Phase Chronic Myelogenous Leukemia that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 70 participants, below the 903-participant average among 11 other Philadelphia Chromosome Positive trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05007873, a Phase 2 study of Philadelphia Chromosome Positive and Chronic Phase Chronic Myelogenous Leukemia, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies the effect of ASTX727 and dasatinib in treating patients with newly diagnosed Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia in chronic phase. Philadelphia chromosome positive and BCR-ABL positive are types of genetic mutations (changes). Chemotherapy drugs, such as ASTX727, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. ASTX727 and dasatinib may help to control Philadelphia chromosome-positive chronic myeloid leukemia or BCR-ABL positive chronic myeloid leukemia in chronic phase.
Primary Outcome
Will be estimated with 95% credible intervals. The association between molecular responses and demographic/ clinical characteristics will be examined by Wilcoxon's rank sum test or Fisher's exact test.
Conditions Studied
Interventions
- DRUG Decitabine and Cedazuridine
- DRUG Dasatinib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2021-10-21 |
| Est. Completion | 2026-10-30 |
| Phase | Phase 2 |
What NCT05007873 shows while recruiting
NCT05007873 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 903-participant average among 11 other Philadelphia Chromosome Positive trials with a reported enrollment target (92% lower).
The record links to 4 conditions, with Philadelphia Chromosome Positive appearing as the primary indexed condition, and to 2 interventions - of which Decitabine and Cedazuridine is the first listed.
NCT05007873 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05007873 about?
NCT05007873 is a clinical study titled "ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase". This phase II trial studies the effect of ASTX727 and dasatinib in treating patients with newly diagnosed Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia in chronic phase. Philadelphia chromosome positive and BCR-ABL positive are types of genetic mutations (changes). Chemotherap...
What is the current status of trial NCT05007873?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2021-10-21. Estimated completion is 2026-10-30.
What conditions does trial NCT05007873 study?
This clinical trial studies the following conditions: Philadelphia Chromosome Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Myelogenous Leukemia, BCR-ABL1 Positive.
What interventions are being tested in trial NCT05007873?
The interventions under investigation include: Decitabine and Cedazuridine (DRUG), Dasatinib (DRUG).
Who is sponsoring clinical trial NCT05007873?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05007873 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Philadelphia Chromosome Positive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05007873's enrollment target sits among peer trials
70 6th of 11 higher than 6 of 11 other Philadelphia Chromosome Positive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Philadelphia Chromosome Positive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
RECRUITING · Phase 2
-
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
ACTIVE NOT RECRUITING · Phase 2
-
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI